Talis Biomedical Corp (TLIS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -192,036 | -163,382 | -124,964 | -60,492 | -91,130 |
| Depreciation Amortization | 1,578 | 641 | 410 | 216 | 763 |
| Accounts receivable | 288 | 252 | 354 | 471 | N/A |
| Accounts payable and accrued liabilities | 216 | 482 | 6,633 | 5,821 | 3,200 |
| Other Working Capital | 8,824 | 25,046 | 64,568 | 35,876 | -951 |
| Other Operating Activity | 9,746 | 6,318 | -2,896 | -4,377 | 1,094 |
| Operating Cash Flow | $-171,384 | $-130,643 | $-55,895 | $-22,485 | $-87,024 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2,866 | -1,879 | -1,120 | -698 | -8,201 |
| Investing Cash Flow | $-2,866 | $-1,879 | $-1,120 | $-698 | $-8,201 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 234,429 | 233,759 | 232,757 | 233,479 | 16 |
| Other Financing Activity | 0 | 0 | 0 | 0 | 246,738 |
| Financing Cash Flow | $234,429 | $233,759 | $232,757 | $233,479 | $246,754 |
| Beginning Cash Position | 173,133 | 173,133 | 173,133 | 173,133 | 21,604 |
| End Cash Position | 233,312 | 274,370 | 348,875 | 383,429 | 173,133 |
| Net Cash Flow | $60,179 | $101,237 | $175,742 | $210,296 | $151,529 |
| Free Cash Flow | |||||
| Operating Cash Flow | -171,384 | -130,643 | -55,895 | -22,485 | -87,024 |
| Capital Expenditure | -2,866 | -1,879 | -1,120 | -698 | -8,201 |
| Free Cash Flow | -174,250 | -132,522 | -57,015 | -23,183 | -95,225 |